Drug Profile
AG 86893
Alternative Names: AG-86893Latest Information Update: 16 Mar 2021
Price :
$50
*
At a glance
- Originator Allgenesis Biotherapeutics
- Class Eye disorder therapies
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Recurrent pterygium
Most Recent Events
- 16 Mar 2021 AG 86893 is still in phase II development for Recurrent pterygium in Australia (Allgenesis Biotherapeutics pipeline, March 2021)
- 25 Oct 2019 Allgenesis Biotherapeutics completes the phase II SURPH trial in Recurrent pterygium in Australia (Ophthalmic) (NCT03533244)
- 11 Oct 2018 Phase-II clinical trials in Recurrent pterygium in Australia (Ophthalmic) (NCT03533244)